Heptavalent Botulism Antitoxin

The Heptavalent Botulism Antitoxin ( H-BAT , spelling of the manufacturer Cangene: Heptavalent Botulism AntiToxin ) is a mixture of seven different antibodies that are used to treat botulism .

properties

With the Heptavalent Botulism Antitoxin, poisoning with botulinum toxins ( serotypes A to G) is treated as a passive immunization . The antibodies were previously purified from sera from immunized horses and partially digested with pepsin . H-BAT is manufactured by the Cangene company. The experimental use in humans was approved in 2010, the general drug approval for the USA took place in 2013 and replaced two previously approved antibody mixtures, the bivalent botulinum antitoxin AB and the monovalent botulinum antitoxin E (BAT-AB and BAT-E).

literature

RG Hibbs, JT Weber, A. Corwin, BM Allos, MS Abd el Rehim, SE Sharkawy, JE Sarn, KT McKee: Experience with the use of an investigational F (ab ') 2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. In: Clinical Infectious Diseases . Volume 23, Number 2, August 1996, ISSN 1058-4838 , pp. 337-340, PMID 8842274 .
RF Robinson, MC Nahata: Management of botulism. In: The Annals of Pharmacotherapy . Volume 37, Number 1, January 2003, ISSN 1060-0280 , pp. 127-131, PMID 12503947 .

Individual evidence

↑ Food and Drug Administration : Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) Treatment of Symptomatic Botulism. BLA 125462. Briefing Document for the Biologic Products Advisory Committee. (PDF) .
↑ Centers for Disease Control and Prevention : Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. In: MMWR. Morbidity and mortality weekly report. Volume 59, Number 10, March 2010, ISSN 1545-861X , p. 299, PMID 20300057 .

[1] Food and Drug Administration : Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) Treatment of Symptomatic Botulism. BLA 125462. Briefing Document for the Biologic Products Advisory Committee. (PDF) .

[2] Centers for Disease Control and Prevention : Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. In: MMWR. Morbidity and mortality weekly report. Volume 59, Number 10, March 2010, ISSN 1545-861X , p. 299, PMID 20300057 .